A detailed history of Federation Des Caisses Desjardins Du Quebec transactions in Biogen Inc. stock. As of the latest transaction made, Federation Des Caisses Desjardins Du Quebec holds 9,106 shares of BIIB stock, worth $1.58 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
9,106
Previous 11,955 23.83%
Holding current value
$1.58 Million
Previous $2.76 Billion 99.92%
% of portfolio
0.01%
Previous 0.02%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$190.52 - $236.72 $542,791 - $674,415
-2,849 Reduced 23.83%
9,106 $2.11 Million
Q1 2024

May 15, 2024

BUY
$212.02 - $267.71 $2.53 Million - $3.2 Million
11,955 New
11,955 $2.76 Billion
Q4 2023

Aug 14, 2024

SELL
$222.59 - $267.94 $1.32 Million - $1.59 Million
-5,924 Reduced 35.84%
10,605 $2.74 Billion
Q3 2023

Aug 14, 2024

SELL
$253.3 - $285.89 $338,408 - $381,949
-1,336 Reduced 7.48%
16,529 $4.25 Billion
Q2 2023

Aug 14, 2024

BUY
$275.25 - $318.06 $1.68 Million - $1.95 Million
6,121 Added 52.12%
17,865 $5.09 Billion
Q1 2023

Aug 14, 2024

BUY
$256.56 - $292.34 $426,402 - $485,869
1,662 Added 16.48%
11,744 $3.27 Billion
Q4 2022

Aug 14, 2024

SELL
$252.44 - $306.72 $11,612 - $14,109
-46 Reduced 0.45%
10,082 $2.79 Billion
Q3 2022

Aug 14, 2024

SELL
$194.69 - $268.46 $652,406 - $899,609
-3,351 Reduced 24.86%
10,128 $2.7 Billion
Q2 2022

Aug 14, 2024

BUY
$187.54 - $223.02 $46,697 - $55,531
249 Added 1.88%
13,479 $2.75 Billion
Q1 2022

Aug 14, 2024

BUY
$193.77 - $244.14 $799,107 - $1.01 Million
4,124 Added 45.29%
13,230 $2.79 Billion
Q4 2021

Aug 30, 2024

SELL
$223.92 - $287.77 $35,155 - $45,179
-157 Reduced 1.16%
13,361 $3.21 Billion
Q3 2021

Aug 30, 2024

SELL
$282.99 - $369.05 $105,555 - $137,655
-373 Reduced 2.69%
13,518 $3.82 Billion
Q2 2021

Aug 30, 2024

BUY
$259.0 - $414.71 $1.24 Million - $1.98 Million
4,785 Added 52.55%
13,891 $4.81 Billion
Q1 2021

Aug 30, 2024

SELL
$242.95 - $284.63 $748,771 - $877,229
-3,082 Reduced 15.12%
17,295 $4.84 Billion
Q4 2020

Aug 30, 2024

BUY
$236.26 - $355.63 $2.19 Million - $3.29 Million
9,265 Added 83.38%
20,377 $4.99 Billion
Q3 2020

Aug 30, 2024

BUY
$264.77 - $305.71 $84,196 - $97,215
318 Added 2.95%
11,112 $3.15 Billion
Q2 2020

Aug 30, 2024

BUY
$258.66 - $342.55 $75,270 - $99,682
291 Added 2.77%
10,794 $2.89 Billion
Q1 2020

Aug 30, 2024

SELL
$268.85 - $341.04 $1.3 Million - $1.65 Million
-4,838 Reduced 31.54%
10,503 $3.32 Billion
Q4 2019

Aug 30, 2024

BUY
$220.06 - $304.07 $162,624 - $224,707
739 Added 5.06%
15,341 $4.55 Billion
Q3 2019

Aug 30, 2024

BUY
$217.44 - $243.88 $1.72 Million - $1.93 Million
7,907 Added 118.1%
14,602 $3.4 Billion
Q2 2019

Aug 30, 2024

SELL
$219.29 - $241.72 $35,305 - $38,916
-161 Reduced 2.35%
6,695 $1.57 Billion
Q1 2019

Aug 30, 2024

SELL
$216.71 - $338.96 $61,328 - $95,925
-283 Reduced 3.96%
6,856 $1.62 Billion
Q4 2018

Aug 30, 2024

SELL
$278.5 - $352.75 $547,809 - $693,859
-1,967 Reduced 21.6%
7,139 $2.15 Billion
Q3 2018

Aug 30, 2024

BUY
$293.51 - $383.83 $304,663 - $398,415
1,038 Added 11.77%
9,858 $3.48 Billion
Q2 2018

Aug 30, 2024

BUY
$257.52 - $306.91 $54,594 - $65,064
212 Added 2.46%
8,820 $2.56 Billion
Q1 2018

Aug 30, 2024

SELL
$260.13 - $367.91 $141,510 - $200,143
-544 Reduced 5.94%
8,608 $2.36 Billion
Q4 2017

Aug 30, 2024

BUY
$307.64 - $344.58 $130,131 - $145,757
423 Added 4.85%
9,152 $2.92 Billion
Q3 2017

Aug 30, 2024

SELL
$281.15 - $329.69 $128,766 - $150,998
-458 Reduced 4.99%
8,729 $2.73 Billion
Q2 2017

Aug 30, 2024

BUY
N/A
576 Added 6.69%
9,187 $2.49 Billion
Q1 2017

Aug 30, 2024

SELL
N/A
-495
8,611 $2.35 Billion

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $25B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Federation Des Caisses Desjardins Du Quebec Portfolio

Follow Federation Des Caisses Desjardins Du Quebec and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.